Rituximab [MabThera/Rituxan]

( DrugBank: Rituximab / KEGG DRUG: Rituximab )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	232

告示番号	疾患名（ページ内リンク）	臨床試験数
63	特発性血小板減少性紫斑病	23

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

trials per page:

Showing 1 to 10 of 232 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2020-002765-34-BE (EUCTR)	21/10/2021	24/08/2021	A Study Comparing MabionCD20 (new Rituximabbiosimilar) with MabThera (reference Rituximabfrom EU) an ...	A Double-Blind, Randomized, Parallel-Group Study to Investigate the Pharmacokinetic and Clinical Sim ...	Moderate-to-severe rheumatoid arthritis MedDRA version: 23.1;Level: PT;Classification code 10039073; ...	Product Name: MabionCD20 INN or Proposed INN: RITUXIMAB Trade Name: MabThera INN or Proposed INN: RITUX ...	Mabion S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	280	Phase 3	Serbia;Poland;Belgium;Ukraine;Bulgaria;Georgia
2	NCT04680962 (ClinicalTrials.gov)	October 17, 2021	2/12/2020	MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis	A Double-Blind, Randomized, Parallel-Group Study to Investigate the Pharmacokinetic and Clinical Sim ...	Rheumatoid Arthritis	Biological: MabionCD20 (candidate biosimilar to rituximab);Biological: MabThera®;Biological: Rituxan ...	Mabion SA	Parexel	Not yet recruiting	18 Years	80 Years	All	280	Phase 3	NULL
3	EUCTR2021-000710-42-NL (EUCTR)	15/03/2021	08/03/2021	Research into the effect of the COVID-vaccine in patients who are treated with rituximab(RTX-COVAC s ...	The RTX-COVAC study: humoral response to COVID-19 vaccination after rituximab, and relation with dos ...	Rheumatoid arthritis MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Trade Name: Comirnaty Trade Name: COVID-19 Vaccine Moderna Product Name: COVID-19 Vaccine Moderna Trade ...	Sint Maartenskliniek	NULL	Not Recruiting			Female: yes Male: yes	270	Phase 4	Netherlands
4	EUCTR2019-002810-37-DE (EUCTR)	23/09/2020	20/02/2020	A study to assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis ...	A Randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safet ...	Rheumatoid Arthritis MedDRA version: 21.0;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Trade Name: Reditux Product Name: Dr. Reddy’s Rituximab(DRL_RI) 100mg Product Code: DRL_RI INN or Propo ...	Dr. Reddy’s Laboratories S.A.	NULL	Not Recruiting			Female: yes Male: yes	140	Phase 3	United States;Hungary;Czech Republic;Poland;Lithuania;Bulgaria;Germany
5	EUCTR2020-002507-19-NL (EUCTR)	07/09/2020	03/09/2020	Research into administration of lower dosed rituximab with an injection	Comparison of subcutaneous and intravenous continued treatment with ultra-low dose Rituximabin rheum ...	rheumatoid arthritis MedDRA version: 21.0;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Trade Name: MabThera Product Name: rituximab Trade Name: Rixathon Product Name: rituximab	Sint Maartenskliniek	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	36	Phase 4	Netherlands
6	NCT05659407 (ClinicalTrials.gov)	July 24, 2020	13/12/2022	BAFF-var as a Biomarker of Response to B-depletive Treatment in Systemic Lupus Erythematosus and Rhe ...	The BAFF-var Polymorphism as a Biomarker of Response to B-depletive Treatment in Patients Affected b ...	Systemic Lupus Erythematosus;Rheumatoid Arthritis;BLyS Polymorphism	Drug: Belimumab in SLE patients / Rituximab in RA patients	University of Cagliari	Azienda Ospedaliero Universitaria di Cagliari	Recruiting	18 Years	N/A	All	60		Italy
7	EUCTR2019-002810-37-PL (EUCTR)	16/06/2020	11/03/2020	A study to assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis ...	A Randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safet ...	Rheumatoid Arthritis MedDRA version: 21.0;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Trade Name: Reditux Product Name: Dr. Reddy’s Rituximab(DRL_RI) 100mg Product Code: DRL_RI INN or Propo ...	Dr. Reddy’s Laboratories S.A.	NULL	Not Recruiting			Female: yes Male: yes	140	Phase 3	United States;Hungary;Estonia;Czech Republic;Poland;Lithuania;Bulgaria;Germany
8	EUCTR2019-002810-37-BG (EUCTR)	15/06/2020	28/04/2020	A study to assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis ...	A Randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safet ...	Rheumatoid Arthritis MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Trade Name: Reditux Product Name: Dr. Reddy’s Rituximab(DRL_RI) 100mg Product Code: DRL_RI INN or Propo ...	Dr. Reddy’s Laboratories S.A.	NULL	Not Recruiting			Female: yes Male: yes	150	Phase 3	United States;Czech Republic;Hungary;Estonia;Poland;Lithuania;Bulgaria;Germany
9	EUCTR2019-002810-37-LT (EUCTR)	17/04/2020	03/03/2020	A study to assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis ...	A Randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safet ...	Rheumatoid Arthritis MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Trade Name: Reditux Product Name: Dr. Reddy’s Rituximab(DRL_RI) 100mg Product Code: DRL_RI INN or Propo ...	Dr. Reddy’s Laboratories S.A.	NULL	Not Recruiting			Female: yes Male: yes	140	Phase 3	United States;Czechia;Hungary;Poland;Lithuania;Bulgaria;Germany
10	NCT04268771 (ClinicalTrials.gov)	April 8, 2020	31/1/2020	A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products	A Randomized, Double-blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safet ...	Rheumatoid Arthritis	Biological: Experimental: Arm A: DRL_RI;Biological: Arm B: Rituxan®/Mabthera®	Dr. Reddy's Laboratories Limited	PPD	Active, not recruiting	18 Years	N/A	All	140	Phase 3	United States

First Previous1 2 3 4 5…24Next Last

63. 特発性血小板減少性紫斑病

臨床試験数 : 391 / 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139

trials per page:

Showing 1 to 10 of 23 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2200057058	2022-07-01	2022-02-27	A Single-Arm Prospective Exploratory Clinical Study Of Zanubrutinib Combined With RituximabIn The Tr ...	A Single-Arm Prospective Exploratory Clinical Study Of Zanubrutinib Combined With RituximabIn The Tr ...	Primary Immune Thrombocytopenia	Therapy Group:Zanubrutinib (80 mg, 2 times/day, for a total of 12 weeks) combined with Rituximab(375 ...	The Second Affiliated Hospital of Kunming Medical University	NULL	Pending	18	70	Both	Therapy Group:23;	Phase 1	China
2	NCT05338190 (ClinicalTrials.gov)	June 1, 2022	21/3/2022	Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximabin Persistent or Ch ...	A Phase 3 Randomized and Double-blind Controlled Trial Comparing the Efficacy and Safety of Subcutan ...	Primary Immune Thrombocytopenia (ITP)	Drug: Combination of Rituximabwith subcutaneous belimumab;Drug: Combination of Rituximabwith subcuta ...	Assistance Publique - Hôpitaux de Paris	GlaxoSmithKline	Not yet recruiting	18 Years	N/A	All	132	Phase 3	NULL
3	ChiCTR2100051890	2021-11-01	2021-10-09	Efficacy and safety analysis of Tetrasip in refractory primary immune thrombocytopenia	Efficacy and safety analysis of Tetrasip in refractory primary immune thrombocytopenia	Primary Immune Thrombocytopenia	Experimental group:Telitacicept;Control group 1:Eltrombopag;Control group 2:Rituximab;	The Second Affiliated Hospital of Kunming Medical University	NULL	Pending	18	60	Both	Experimental group:20;Control group 1:20;Control group 2:20;	Phase 4	China
4	ChiCTR2000035408	2020-08-20	2020-08-10	A randomized controlled study for rituximabin first-line treatment of newly diagnosed immune thrombo ...	Study of rituximab in first-line treatment of newly diagnosed immune thrombocytopenia	Idiopathic Thrombocytopenic Purpura	Standard dose group:Rituximab(Hanrikang) 375mg/m2, 4 times a week (day 8, 15, 22, 29).;Low-dose grou ...	Henan Cancer Hospital	NULL	Recruiting	18	65	Both	Standard dose group:20;Low-dose group:20;Dexamethasone control group:20;	Phase 4	China
5	NCT04518475 (ClinicalTrials.gov)	August 10, 2020	12/8/2020	Eltrombopag Combining RituximabVersus Eltrombopag in the Management of Primary Immune Thrombocytopen ...	A Multicenter, Randomized, Open-label Study To Compare The Efficacy And Safety Of Eltrombopag Combin ...	Primary Immune Thrombocytopenia (ITP)	Drug: eltrombopag combining rituximab;Drug: eltrombopag	Institute of Hematology & Blood Diseases Hospital	The Second Affiliated Hospital of Kunming Medical University;Henan Cancer Hospital;Tianjin Medical U ...	Recruiting	18 Years	60 Years	All	224	Phase 4	China
6	ChiCTR1900027748	2020-05-01	2019-11-25	A single-arm multicenter prospective clinical study of rituximab500 mg/m2 in glucocorticoid-ineffect ...	A single-arm multicenter prospective clinical study of rituximab500 mg/m2 in glucocorticoid-ineffect ...	Primary Immune Thrombocytopenia	Test group:Rituximab (500mg/m2, once intravenously);	Department of Hematology, the Second Affiliated Hospital of Kunming Medical University	NULL	Recruiting			Both	Test group:60;	Phase 4	China
7	ChiCTR2000030603	2020-05-01	2020-03-08	A multicenter prospective cohort clinical study of a short-course glucocorticoid therapy regimen for ...	A multicenter prospective cohort clinical study of a short-course glucocorticoid therapy regimen for ...	Primary Immune Thrombocytopenia	The short -course glucocorticoid group:treat with glucocorticoid;The eltrombopag group:treat with el ...	The Second Affiliated Hospital of Kunming Medical University	NULL	Recruiting	18	75	Both	The short -course glucocorticoid group:65;The eltrombopag group:65;The rituximab group:65;Splenectomy group:65;The azathioprine group:65;The cyclosporine group:65;	Phase 4	China
8	NCT03443570 (ClinicalTrials.gov)	March 1, 2018	18/2/2018	Rituximab Combining Bortezomib Versus Rituximab in Management of ITP	A Multicenter Prospective Randomized Study of RituximabCombined With Bortezomib Versus Rituximabin t ...	Immune Thrombocytopenia;Purpura, Thrombocytopenic, Idiopathic	Drug: Rituximab;Drug: Bortezomib	Shandong University	The Affiliated Hospital of Qingdao University;Yantai Yuhuangding Hospital	Not yet recruiting	18 Years	75 Years	All	200	Phase 3	China
9	EUCTR2015-005276-14-DK (EUCTR)	08/12/2016	19/10/2016	Maintenance treatment With rituximab in ITP	Prolonging the response by low-dose Rituximabmaintenance therapy in immune thrombocytopenia: a rando ...	Immune thrombocytopenia MedDRA version: 23.0;Level: LLT;Classification code 10021245;Term: Idiopathi ...	Trade Name: Mabthera Product Name: rituximab Trade Name: Dexamethasone Abcur Product Name: Dexamethason ...	Sykehuset Østfold HF	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	France;Egypt;Denmark;Norway;Tunisia
10	NCT01734057 (ClinicalTrials.gov)	July 2012	21/11/2012	Recombinant Human Thrombopoietin (rhTPO) Combining RituximabVersus High-dose Dexamethasone for Initi ...	A Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining RituximabVersus Hi ...	Purpura;Idiopathic Thrombocytopenic Purpura	Drug: recombinant human thrombopoietin (rhTPO); rituximab;Drug: Dexamethasone	Shandong University	The Affiliated Hospital of the Chinese Academy of Military Medical Sciences;Anhui Medical University ...	Withdrawn	18 Years	75 Years	Both	0	Phase 3	China

First Previous1 2 3Next Last